Tazemetostat in combination with lenalidomide and rituximab for R/R follicular lymphoma

Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, speaks about the launch of the Phase III SYMPHONY-1 study (NCT04224493), investigating the combination of tazemetostat, lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma (R/R FL). Dr Nastoupil discusses the data seen with tazemetostat, an oral EZH2 inhibitor, in Phase I/II studies and explains the rationale for this therapeutic combination. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.